Advertisement

 

 

SDF1 Polymorphisms Influence Outcome in Patients with Symptomatic Cardiovascular Disease.

SDF1 Polymorphisms Influence Outcome in Patients with Symptomatic Cardiovascular Disease.
Author Information (click to view)

Rath D, Schaeffeler E, Winter S, Hewer J, Müller K, Droppa M, Stimpfle F, Gawaz M, Schwab M, Geisler T,


Rath D, Schaeffeler E, Winter S, Hewer J, Müller K, Droppa M, Stimpfle F, Gawaz M, Schwab M, Geisler T, (click to view)

Rath D, Schaeffeler E, Winter S, Hewer J, Müller K, Droppa M, Stimpfle F, Gawaz M, Schwab M, Geisler T,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PloS one 2016 09 0811(9) e0161933 doi 10.1371/journal.pone.0161933

Abstract
BACKGROUND
SDF1 and its cognate receptors CXCR4 and CXCR7 are involved in myocardial repair and are associated with outcome in cardiovascular patients. Hence, we aimed to investigate clinically significant SDF1 SNPs for their prognostic impact in patients with cardiovascular disease.

METHODS AND RESULTS
Genotyping for selected SDF1 variants (rs1065297, rs2839693, rs1801157, rs266087, rs266085 and rs266089 was performed in patients (n = 872) who underwent percutaneous coronary intervention. Carriers of variant rs2839693 and rs266089 showed significantly higher cumulative event-free survival compared with non-carriers. All other polymorphisms had no relevant influence on outcome. Multivariate Cox regression analysis showed a significant correlation of these SNPs with cardiovascular outcome after inclusion of clinical and prognostic relevant variables (hazard ratio (HR) 0.51 (95% CI 0.30-0.88), p = 0.015 and [HR 0.51 (95% CI 0.30-0.88), p = 0.016, respectively). In addition, multivariate Cox regression with SDF1 haplotypes revealed a significantly reduced risk for the haplotype carrying the minor alleles of rs2839693 and rs266089 (HR 0.47 (95% CI 0.27-0.84), p = 0.011).

CONCLUSION
Distinct SDF1 polymorphisms are associated with improved cardiovascular prognosis in CAD patients. Further studies are warranted to validate these results and to better describe the endogenous regeneration potential in carriers of these SNPs. Targeted, genotype guided therapeutic approaches to foster myocardial regeneration and thus cardiovascular prognosis should be evaluated in future.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 × 1 =

[ HIDE/SHOW ]